Business Context and Reporting Period
Company: ROBO.AI INC.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: May 2026 (Event date: May 4, 2026; Filing date: May 7, 2026)
Principal Executive Offices: Dubai, United Arab Emirates
The Company entered into a definitive share purchase agreement to acquire 100% of the equity of Neurovia AI Limited, a British Virgin Islands-based technology company specializing in data processing and compression.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity) for the reporting period. The primary financial metric disclosed relates to the transaction consideration:
- Total Consideration: US$100,000,000
- Payment Method: Issuance of 149,097,957 Class B ordinary shares of the Company
- Debt Impact: No cash debt incurred for this transaction; consideration is equity-based.
Material Changes
The material change reported is the strategic acquisition of Neurovia AI Limited. This transaction represents a significant expansion of the Company's technology portfolio and international commercialization capabilities in intelligent hardware and mobility solutions. The transaction is contingent upon the satisfaction or waiver of all conditions precedent.
Guidance, Outlook, and Transaction Terms
Strategic Outlook: The acquisition is intended to support technology development efforts and facilitate the international commercialization of intelligent hardware and mobility solutions.
Transaction Terms:
- Closing Date: On or before June 16, 2026, or a later date mutually agreed in writing.
- Lock-Up Period: The Consideration Shares are subject to an 8-year lock-up period commencing on the closing date.
- Release Schedule:
- Years 1–4: Absolutely no release of shares.
- Years 5–8: Shares released in five equal annual tranches on each anniversary after the closing date, starting from the fourth anniversary.
Risks and Contingencies: The transaction is subject to conditions precedent. The summary is qualified by the full Share Purchase Agreement filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the exact closing date and whether all conditions precedent have been satisfied by June 16, 2026.
- Review the full Share Purchase Agreement (Exhibit 99.1) for specific representations, warranties, and indemnification clauses.
- Assess the dilution impact of issuing 149,097,957 new Class B ordinary shares on existing shareholders.
- Confirm the financial health and technology assets of Neurovia AI Limited to validate the US$100 million valuation.
- Monitor future filings for the actual issuance of Consideration Shares and any changes to the lock-up schedule.